Pacific Biosciences Of California (PACB) Payables (2010 - 2026)

Pacific Biosciences Of California's Payables history runs 17 years deep, the most recent figure standing at $13.6 million for Q1 2026.

• In Q1 2026, Payables fell 3.05% year-over-year to $13.6 million; the TTM figure through Mar 2026 stood at $13.6 million (down 3.05% YoY), while the FY2025 annual figure was $20.8 million, up 25.2% from the prior year.
• Payables was $13.6 million for Q1 2026 at Pacific Biosciences Of California, down from $20.8 million in the prior quarter.
• In the past five years, Payables ranged from a high of $21.0 million in Q1 2024 to a low of $12.1 million in Q3 2024.
• Historically, Payables has averaged $15.9 million across 5 years, with a median of $16.1 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Payables surged 407.26% in 2022, then slumped 33.18% in 2025.
• A 5-year view of Payables shows it stood at $14.3 million in 2022, then advanced by 8.61% to $15.6 million in 2023, then grew by 6.61% to $16.6 million in 2024, then grew by 25.2% to $20.8 million in 2025, then plunged by 34.48% to $13.6 million in 2026.
• The last three Payables figures came in at $13.6 million (Q1 2026), $20.8 million (Q4 2025), and $16.4 million (Q3 2025), per Business Quant data.